A-Hyeon Lee

Ms. A-Hyeon Lee

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
JOJu Hee Oh
Ju Hee Oh
WSWaqar Khalid Saeed
Waqar Khalid Saeed
HKHye Young Kim
Hye Young Kim
SLSeung Min Lee
Seung Min Lee
ALA Hyeon Lee
A Hyeon Lee
DJDae Won Jun
Dae Won Jun

29 March 2024 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
KIKeon Hwi Im
Keon Hwi Im
WSWaqar K. Saeed
Waqar K. Saeed
EKEun Bin Kim
Eun Bin Kim
ALA-Hyeon Lee
A-Hyeon Lee
JKJi Eun Kim
Ji Eun Kim
EYEileen Yoon
Eileen Yoon

8 October 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
ALA-Hyeon Lee
A-Hyeon Lee
SLSeung Min Lee
Seung Min Lee
IKIn Young Kang
In Young Kang
GPGye Ryeol Park
Gye Ryeol Park
Hye Hyun YooHye Hyun Yoo
Hye Hyun Yoo
DJDae Won Jun
Dae Won Jun
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease, and its global incidence continues to increase. MASLD can progress from simple steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, effective preventive and therapeutic options remain limited. In this study, obeticholic acid (OCA) and the probiotic mixture VSL#3 were co-administered to a mouse model of MASLD to modulate gut microbiota and bile acid metabolism. Methods: Male C57BL/6 mice were fed a WD to induce MASLD and treated with OCA, VSL#3, or both. Gut microbiota was analyzed by 16S rRNA sequencing, bile acid (BA) composition was assessed by LC–MS/MS, hepatic and intestinal gene expression was determined by quantitative real-time PCR (qPCR) and immunohistochemistry, and unconjugated OCA pharmacokinetics (PK) were evaluated. Results: VSL#3-containing groups showed differences in selected taxa with reported bile salt hydrolase (BSH) potential and in BA composition, including a numerical shift toward higher levels of deconjugated BAs. Co-administration of OCA and VSL#3 was accompanied by lower hepatic steatosis, numerically favorable serum markers of liver injury, and lower cholesterol and total bilirubin levels. In addition, mice receiving VSL#3 showed numerically higher early plasma concentrations of unconjugated OCA. Lower intestinal ATP-binding cassette subfamily C member 2 (Abcc2) expression was also observed as a separate exploratory finding. Conclusions: The co-administration of VSL#3 with OCA was accompanied by exploratory differences in selected biological parameters and early-phase unconjugated OCA exposure. Lower intestinal Abcc2/Mrp2 expression was observed as a separate exploratory finding, and no functional relationship between intestinal transporter expression and OCA pharmacokinetics was established.